[{"id":"597f3d3b-7b1b-4903-87c4-f3117fd83b5e","acronym":"topMIND","url":"https://clinicaltrials.gov/study/NCT04809467","created_at":"2021-03-22T11:52:17.035Z","updated_at":"2024-07-02T16:34:37.699Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT04809467 - topMIND","lead_sponsor":"Incyte Corporation","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-06-06"},{"id":"0fe10839-16f3-4ebf-97c8-7feb7f85fc90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083208","created_at":"2021-10-19T15:58:00.734Z","updated_at":"2024-07-02T16:35:05.553Z","phase":"Phase 1/2","brief_title":"PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT05083208","lead_sponsor":"Henan Cancer Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • parsaclisib (INCB50465)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 02/20/2022","start_date":" 02/20/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-07"},{"id":"5c8406ae-f056-4f83-9353-3927df966f6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04774068","created_at":"2021-02-26T12:55:20.808Z","updated_at":"2024-07-02T16:35:06.559Z","phase":"Phase 1","brief_title":"Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas","source_id_and_acronym":"NCT04774068","lead_sponsor":"Walter Hanel","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • parsaclisib (INCB50465)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-01"},{"id":"26065744-c262-4f87-91b1-e6294c2cfbc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323956","created_at":"2021-01-18T20:56:54.236Z","updated_at":"2024-07-02T16:35:31.265Z","phase":"Phase 1","brief_title":"Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04323956","lead_sponsor":"Mayo Clinic","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2023-10-30"},{"id":"001f0711-6549-4919-ac50-28efedc49619","acronym":"","url":"https://clinicaltrials.gov/study/NCT03314922","created_at":"2021-07-02T18:53:23.826Z","updated_at":"2024-07-02T16:35:40.410Z","phase":"Phase 1b","brief_title":"A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)","source_id_and_acronym":"NCT03314922","lead_sponsor":"Incyte Corporation","biomarkers":" IL10","pipe":"","alterations":" ","tags":["IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e parsaclisib (INCB50465)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/02/2018","start_date":" 08/02/2018","primary_txt":" Primary completion: 05/05/2020","primary_completion_date":" 05/05/2020","study_txt":" Completion: 03/09/2023","study_completion_date":" 03/09/2023","last_update_posted":"2023-08-10"},{"id":"b85b8ed9-ff66-4925-a28a-fde501ca6148","acronym":"","url":"https://clinicaltrials.gov/study/NCT05073250","created_at":"2021-10-11T12:53:00.937Z","updated_at":"2024-07-02T16:35:48.085Z","phase":"Phase 2","brief_title":"IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.","source_id_and_acronym":"NCT05073250","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • parsaclisib (INCB50465)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-05-12"},{"id":"ca9a24a9-fca8-4fdc-9ecd-ef5a847c7a80","acronym":"CITADEL-310","url":"https://clinicaltrials.gov/study/NCT04849715","created_at":"2021-04-19T11:53:03.799Z","updated_at":"2024-07-02T16:36:11.219Z","phase":"Phase 3","brief_title":"A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT04849715 - CITADEL-310","lead_sponsor":"Incyte Corporation","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • parsaclisib (INCB50465) • Belrapzo (bendamustine RTD)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 08/15/2030","primary_completion_date":" 08/15/2030","study_txt":" Completion: 07/07/2034","study_completion_date":" 07/07/2034","last_update_posted":"2022-04-29"},{"id":"13897862-4c02-48ae-ae66-7b8e616b8340","acronym":"","url":"https://clinicaltrials.gov/study/NCT02646748","created_at":"2021-01-18T12:52:44.723Z","updated_at":"2024-07-02T16:36:14.414Z","phase":"Phase 1","brief_title":"Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors","source_id_and_acronym":"NCT02646748","lead_sponsor":"Incyte Corporation","biomarkers":" EGFR • ALK • FOXP3","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • parsaclisib (INCB50465) • itacitinib (INCB039110)"],"overall_status":"Completed","enrollment":" Enrollment 159","initiation":"Initiation: 01/25/2016","start_date":" 01/25/2016","primary_txt":" Primary completion: 11/07/2019","primary_completion_date":" 11/07/2019","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2022-03-31"},{"id":"b6abc1be-d58c-47f0-9c9c-050fb3f045d9","acronym":"CITADEL-102","url":"https://clinicaltrials.gov/study/NCT03039114","created_at":"2021-01-18T14:57:50.420Z","updated_at":"2024-07-02T16:36:19.968Z","phase":"Phase 1","brief_title":"Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)","source_id_and_acronym":"NCT03039114 - CITADEL-102","lead_sponsor":"Incyte Corporation","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • bendamustine • parsaclisib (INCB50465)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 02/15/2017","start_date":" 02/15/2017","primary_txt":" Primary completion: 03/30/2021","primary_completion_date":" 03/30/2021","study_txt":" Completion: 03/30/2021","study_completion_date":" 03/30/2021","last_update_posted":"2021-12-02"},{"id":"e6253387-0915-44dd-9ad3-c9a28b481d2a","acronym":"LCCC1820","url":"https://clinicaltrials.gov/study/NCT04142554","created_at":"2021-01-18T20:13:15.815Z","updated_at":"2024-07-02T16:36:39.217Z","phase":"Phase 1","brief_title":"Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer","source_id_and_acronym":"NCT04142554 - LCCC1820","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" HER-2 • CD8","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 negative • EGFR positive","tags":["HER-2 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e parsaclisib (INCB50465)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 09/07/2020","primary_completion_date":" 09/07/2020","study_txt":" Completion: 09/07/2020","study_completion_date":" 09/07/2020","last_update_posted":"2020-11-03"}]